Prognostic Factors in Metastatic Renal Cell Carcinoma: Metastasectomy As Independent Prognostic Variable

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Aug 31

PMID 16940978

Citations 30

Authors

U M Vogl

H Zehetgruber

M Dominkus

M Hejna

C C Zielinski

A Haitel

M Schmidinger

Affiliations

Soon will be listed here.

Abstract

Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated patients or patients on several different treatment approaches. The aim of this analysis was to define prognostic and predictive factors in patients treated uniformly with a low-dose outpatient cytokine combination. The relationship between patient-, tumour-, and treatment-related factors was analysed in 99 patients with MRCC. These features were first examined in univariate analyses, then a stepwise modelling approach based on Cox regression was used to form a multivariate model. Nuclear grade, metastasectomy--even incomplete--C-reactive protein and lactate dehydrogenase were identified as independent prognostic factors for survival. Patients assigned to three different risk groups had statistically significant survival differences (30, 22 and 6 months, respectively). A total of 43.4% had undergone metastasectomy, mostly incomplete. Risk group affiliation was correlated with response to treatment. Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer undergoing either immunotherapy or targeted treatment.

Citing Articles

Prognostic value and model construction of preoperative inflammatory markers in patients with metastatic renal cell carcinoma.

Wang J, Ye J, Zhao X, Li X, Ma X World J Surg Oncol. 2023; 21(1):211.

PMID: 37480143 PMC: 10360324. DOI: 10.1186/s12957-023-03110-w.

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.

Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone A Cancer Manag Res. 2022; 14:3071-3081.

PMID: 36275783 PMC: 9584769. DOI: 10.2147/CMAR.S360441.

The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.

Franzese C, Marini B, Baldaccini D, Badalamenti M, Navarria P, Bellu L J Cancer Res Clin Oncol. 2022; 149(8):4411-4417.

PMID: 36109401 DOI: 10.1007/s00432-022-04352-z.

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.

Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T Int J Clin Oncol. 2022; 27(3):563-573.

PMID: 34973106 PMC: 8882566. DOI: 10.1007/s10147-021-02091-8.

miR-30b-5p up-regulation related to the dismal prognosis for patients with renal cell cancer.

Zhang C, Pan X, Peng X, Liu K, Wang J, Zhao L J Clin Lab Anal. 2020; 35(2):e23599.

PMID: 33247622 PMC: 7891535. DOI: 10.1002/jcla.23599.

References

Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J . Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40. DOI: 10.1200/JCO.1999.17.8.2530. View

Motzer R, Michaelson M, Redman B, Hudes G, Wilding G, Figlin R . Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 24(1):16-24. DOI: 10.1200/JCO.2005.02.2574. View

Duffaud F, Therasse P . [New guidelines to evaluate the response to treatment in solid tumors]. Bull Cancer. 2001; 87(12):881-6. View

Lissoni P, ROVELLI F, Baiocco N, Tangini G, Fumagalli L . A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res. 2001; 21(1B):777-9. View

Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi J . Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001; 61(13):5090-101. View

Atzpodien J, Royston P, Wandert T, Reitz M . Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003; 88(3):348-53. PMC: 2747541. DOI: 10.1038/sj.bjc.6600768. View

Motzer R, Amato R, Todd M, Hwu W, Cohen R, Baselga J . Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003; 21(1):99-101. DOI: 10.1023/a:1022928612511. View

Yang J, Sherry R, Steinberg S, Topalian S, Schwartzentruber D, Hwu P . Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21(16):3127-32. PMC: 2275327. DOI: 10.1200/JCO.2003.02.122. View

Motzer R, Bacik J, Schwartz L, Reuter V, Russo P, Marion S . Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22(3):454-63. DOI: 10.1200/JCO.2004.06.132. View

10.

Kedar I, Mermershtain W, Ivgi H . Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer. 2004; 110(2):260-5. DOI: 10.1002/ijc.20089. View

11.

Motzer R, Bacik J, Mazumdar M . Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res. 2004; 10(18 Pt 2):6302S-3S. DOI: 10.1158/1078-0432.CCR-040031. View

12.

Yang J . Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004; 10(18 Pt 2):6367S-70S. DOI: 10.1158/1078-0432.CCR-050006. View

13.

Neves R, Zincke H, Taylor W . Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol. 1988; 139(6):1173-6. DOI: 10.1016/s0022-5347(17)42851-5. View

14.

Blay J, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y . Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52(12):3317-22. View

15.

Simpson W, Heys S, Whiting P, Eremin O, Broom J . Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol. 1995; 99(2):143-7. PMC: 1534287. DOI: 10.1111/j.1365-2249.1995.tb05524.x. View

16.

Tartour E, Blay J, Dorval T, Escudier B, Mosseri V, Douillard J . Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol. 1996; 14(5):1697-703. DOI: 10.1200/JCO.1996.14.5.1697. View

17.

Ljungberg B, Grankvist K, Rasmuson T . Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer. 1995; 76(8):1435-9. DOI: 10.1002/1097-0142(19951015)76:8<1435::aid-cncr2820760821>3.0.co;2-y. View

18.

Papadopoulos I, Rudolph P, Wirth B, Weichert-Jacobsen K . p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology. 1996; 48(2):261-8. DOI: 10.1016/S0090-4295(96)00169-0. View

19.

Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U . Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol. 1997; 31(3):286-91. DOI: 10.1159/000474469. View

20.

Thiounn N, Pages F, Flam T, Tartour E, Mosseri V, Zerbib M . IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett. 1997; 58(2):121-4. DOI: 10.1016/s0165-2478(97)00036-9. View